Sentry Investment Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Sentry Investment Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-869	Closed	-$2K	–	456
2020 Q3	$2K	Hold	869	–	–	﹤0.01%	425
2020 Q2	$3K	Hold	869	–	–	﹤0.01%	460
2020 Q1	$3K	Hold	869	–	–	﹤0.01%	419
2019 Q4	$3K	Buy	+869	New	+$2.26K	﹤0.01%	439

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Sentry Investment Management's BMY.RT Position: Q4 2020 in Review

Sentry Investment Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 869 shares — an estimated $2K sold.

Sentry Investment Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $3K in Q2 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Sentry Investment Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Sentry Investment Management sold 869 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $2K.
Sentry Investment Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
Sentry Investment Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3K in Q2 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Sentry Investment Management's 13F filing for Q4 2020, filed 2 Feb 2021.